Layer, Chiang, et al. Genome Biology
Calando Says Strength of Phase I Trial of CALAA-01 Will Attract Partners, Including Suitors
Although in the short term it will continue to focus on CALAA-01, the siRNA-based drug expected to create partnerships for Calando, Arrowhead is considering initiating new drug-development programs.
New to GenomeWeb? Register here quickly.